Versus semaglutide (GLP-1 mono-agonist) : considerable gap
There is large inter-person variability in response to GLP1 medications both in terms of weight loss and side effects, with the two potentially being related (that is, people who experience more nausea may lose more weight 30 )
As Habener explains, 'Previous studies in animals had shown that GLP-1 slowed down acid secretion and stomach emptying and caused early satiety
In my private practice, I started using GLP-1 drugs such as exenatide in 2006 and liraglutide in 2010 for my patients with type 2 diabetes
A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes trials, retrospective database analyses, meta-analyses and preclinical studies involving semaglutide, liraglutide, dulaglutide and related agents across six ocular conditions: diabetic retinopathy (DR), glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH) and dry eye disease (DED)
[28] [29] Establishing clear communication channels and understanding when to seek medical advice helps ensure safe concurrent use of these important medication classes
